Becton Dickinson ensures Retractable doesn't have its day in court
This article was originally published in Clinica
Retractable Technologies has agreed to settle its federal antitrust suit against Becton Dickinson for $100m in cash, only days before the case was scheduled to go to trial. The lawsuit was dismissed with prejudice against BD in the US District Court in Texarkana, Texas on July 2.
You may also be interested in...
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.
Shanghai Henlius Biotech has announced that China’s NMPA has accepted the firm’s filing for its HLX14 denosumab biosimilar. Meanwhile, the company has also announced dosing the first patient in a Phase II clinical trial of its novel HLX10 anti-PD-1 monoclonal antibody.